Celcuity+Logo.jpg
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 27, 2024 16:01 ET | Celcuity Inc.
Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic castration resistant prostate cancer Presented nonclinical data...
AIMLogo.jpg
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
March 22, 2024 08:55 ET | AIM ImmunoTech Inc.
OCALA, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
Celcuity+Logo.jpg
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call
March 20, 2024 07:05 ET | Celcuity Inc.
MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
LUDG.png
Ludwig Enterprises Inc (OTC:LUDG) Enters Booming Artificial Intelligence Cancer Screening Market with its Non-Invasive Cancer Diagnostics Testing Kit, launching within 2024
March 19, 2024 08:00 ET | Ludwig Enterprises, Inc.
SPARKS, Nev., March 19, 2024 (GLOBE NEWSWIRE) -- Ludwig Enterprises, Inc, (OTC: LUDG): A US-based biotechnology company is pleased to announce it has entered the booming artificial intelligence...
Bionano_RGB.png
Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance
March 19, 2024 08:00 ET | Bionano Genomics
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study of optical genome mapping (OGM) in hereditary breast and ovarian cancer...
AIMLogo.jpg
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
March 15, 2024 08:45 ET | AIM ImmunoTech Inc.
OCALA, Fla., March 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that it will present at the Virtual Investor Lunch Break: The AIM...
U.S. Cancer Contrast Media Market
United States Cancer Contrast Media Research Analysis Report 2024-2030: Increasing Number of Clinical Studies, Rising Cancer Cases, Collaborations and Partnerships, Technological Advancements
March 14, 2024 12:05 ET | Research and Markets
Dublin, March 14, 2024 (GLOBE NEWSWIRE) -- The "U.S. Cancer Contrast Media Market Size, Share & Trends Analysis Report by Type (Gadolinium-based Contrast Media, Iodinated Contrast Media),...
Global Interventional Oncology Market
Global Interventional Oncology Market Anticipates Explosive Growth, Forecasted at $8.06 Billion by 2034 - Regional Insights for Products, Cancer Types, and End-users
March 12, 2024 12:39 ET | Research and Markets
Dublin, March 12, 2024 (GLOBE NEWSWIRE) -- The "Global Interventional Oncology Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. The global...
Olema_Oncology_HIGH RES LOGO.png
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
March 11, 2024 16:03 ET | Olema Oncology
Presented compelling clinical results for palazestrant both as a monotherapy and in combination with CDK4/6 inhibitors, ribociclib and palbociclib, in Q4 2023 Initiated OPERA-01 pivotal Phase 3...
Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market
Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market 2023-2032: Liquid Biopsy for Breast Cancer Diagnosis and Complete Automation of Next-Generation Techniques are the Key Trends
March 11, 2024 13:17 ET | Research and Markets
Dublin, March 11, 2024 (GLOBE NEWSWIRE) -- The "Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market: Analysis and Forecast, 2023-2032" report has been added to ...